Pharsight

Cosela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11717523 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11529352 G1 THERAP Preservation of immune response during chemotherapy regimens
Jul, 2039

(15 years from now)

Cosela is owned by G1 Therap.

Cosela contains Trilaciclib Dihydrochloride.

Cosela has a total of 12 drug patents out of which 0 drug patents have expired.

Cosela was authorised for market use on 12 February, 2021.

Cosela is available in powder;intravenous dosage forms.

Cosela can be used as a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer, a method for reducing the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhibitor for extensive-stage small cell cancer.

Drug patent challenges can be filed against Cosela from 12 February, 2025.

The generics of Cosela are possible to be released after 23 July, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A m...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

Family Patents